Actividad antimicrobiana in vitro de los vinos del Duero sobre cepas clínicas de Helicobacter Pylori

Autores/as

  • Lidia Po Catalao Dionisio
  • Alejandro Manuel Labella Universitario Teatinos
  • María Palma Universidade do Algarve
  • Juan José Borrego

DOI:

https://doi.org/10.22490/24629448.5499

Palabras clave:

Helicobacter pylori, antioxidantes, actividad antimicrobiana, vinos del Duero, resveratrol, proantocianidinas

Resumen

Objetivo. Se evaluó las actividades antimicrobianas in vitro de siete vinos (5 tintos y 2 blancos) de la región del Duero (Peninsula Ibérica) frente a once cepas de Helicobacter pylori de origen clínico.

Métodos. Para determinar las propiedades antimicrobianas de algunos componentes del vino sobre las cepas de H. pylori se utilizaron las técnicas de difusión en disco en placas de agar Columbia suplementado con sangre de caballo (CAB). La potential interacción entre las sustancias antioxidantes presentes en los vinos y dos antimicrobianos (amoxicilina y metronidazol) se determinó usando la técnica de difusión en disco.

Resultados. Todas las cepas ensayadas mostraron crecimiento en CAB suplementado con el 9% de los vinos analizados, pero no se obtuvo crecimiento de ninguna de las cepas en medios suplementados con el 45% y el 67,5% de vino. Asimismo, todas las cepas ensayadas crecieron en medios con la concentración de proantocianidinas presentes en los diferentes tipos de vinos estudiados. Los valores de concentración mínima inhibitoria (CMI) de los componentes antioxidantes de los vinos ensayados (ácido benzoico, catequina, quercetina y resveratrol) indican que el resveratrol fue la sustancia más potente en la inhibición del crecimiento de H. pylori. También se estableció un efecto de potenciación entre amoxicilina y metronidazol y los antioxidantes ensayados. Las interacciones amoxicilina + resveratrol y metronidazol + catequina aumentaron la actividad antimicrobiana contra H. pylori. Conclusiones. Los resultados obtenidos sugieren un papel potencial del resveratrol como agente quimiopreventivo de la infección por H. pylori.

Biografía del autor/a

Lidia Po Catalao Dionisio

PhD in Biology. MED-Mediterranean Institute for Agriculture, Environment and Development. Pólo do Algarve. Campus de Gambelas

Alejandro Manuel Labella , Universitario Teatinos

PhD in Microbiology. Department of Microbiology, University of Malaga, Campus Universitario Teatinos, 29071-Malaga, Spain

María Palma , Universidade do Algarve

PhD in Food Consumption and Nutrition. Escola Superior de Saúde da Universidade do Algarve, Campus de Gambelas 8005, 139-Faro, Portugal

Juan José Borrego

PhD in Microbiology. Department of Microbiology, University of Malaga, Campus Universitario Teatinos, 29071-Malaga, Spain.

Citas

Kusters JG, van Vliet AHM, Kuipers E. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006; 19:449-490. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539101/pdf/0054-05.pdf

Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol. 2002; 3:97-104. https://www.sciencedirect.com/science/article/pii/S1470204502006514?via%3Dihub

Sachs G, Weeks DL, Melchers K, Scott DR. The gastric biology of Helicobacter pylori. Annu Rev Physiol. 2003; 65:349-369. https://www.annualreviews.org/doi/pdf/10.1146/annurev.physiol.65.092101.142156

Dundon WG, de Bernard M, Montecucco C. Virulence factors of Helicobacter pylori. Int J Med Microbiol. 2001; 290:647-658. doi: 10.1016/s1438-4221(01)80002-3.

Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 1999; 13:857-864. https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2036.1999.00542.x

Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16:167-180. https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2036.2002.01169.x

Debets-Ossenkopp YJ, Namavar F, MacLaren DM. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1995; 14:353-355. doi: 10.1007/BF02116532.

Gerrits MM, van Vliet AHM, Kuipers E, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. The Lancet Infect Dis. 2006; 6:699-709. https://www.sciencedirect.com/science/article/pii/S1473309906706272?via%3Dihub

Macias-Garcia F, Llovo-Taboada J, Diaz-Lopez M, Baston-Rey I, Dominguez-Munoz JE. High primary antibiotic resistance of Helicobacter pylori strains isolated from dyspeptic patients: a prevalence cross-sectional study in Spain. Helicobacter. 2017;22: e12440. https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.12440

Alba C, Blanco A, Alarcon T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;30: 489-497. https://journals.lww.com/co-infectiousdiseases/Fulltext/2017/10000/Antibiotic_resistance_in_Helicobacter_pylori.8.aspx

Walduck AK, Raghavan S. Immunity and vaccine development against Helicobacter pylori. In: Kamiya S, Backert S, eds. Helicobacter pylori in Human Diseases. Advances in Experimental Medicine and Biology, vol 1149, Cham.: Springer; 2019. p. 257-275. https://link.springer.com/chapter/10.1007%2F5584_2019_370

Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents. 2005; 25:385-391. https://www.sciencedirect.com/science/article/pii/S0924857905000312?via%3Dihub

Stojilijkovic I, Evavold BD. (2001) Antimicrobial properties of porphyrins. Expert Opin Investig Drugs. 2001; 10:309-320. https://www.tandfonline.com/doi/abs/10.1517/13543784.10.2.309

Ohno T, Kita M, Yamaoka Y, Imamura S, Yamamoto T, Mitsufuji S, et al. Antimicrobial activity of essential oils against Helicobacter pylori. Helicobacter. 2003; 8:207-215. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1523-5378.2003.00146.x?sid=nlm%3Apubmed

Tombola F, Campello S, De Luca L, Ruggiero P, Del Giudice G, Papini E, et al. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen Helicobacter pylori. FEBS Lett. 2003; 543:184-189. https://febs.onlinelibrary.wiley.com/doi/full/10.1016/S0014-5793%2803%2900443-5?sid=nlm%3Apubmed

Eurogast Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut. 1993; 34:1672- 1676. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374460/

Brenner H, Rothenbacher D, Bode G, Adler G. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: Cross sectional study. Br Med J. 1997; 315:1489-1492. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2127930/

Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000; 95:3374-3382. https://insights.ovid.com/pubmed?pmid=11151864

Brenner H, Bode G, Adler G, Hoffmeister A, Koenig W, Rothenbacher D. Alcohol as a gastric disinfectant? The complex relationship between alcohol consumption and current Helicobacter pylori infection. Epidemiology. 2001; 12:209-214. https://journals.lww.com/epidem/Fulltext/2001/03000/Alcohol_as_a_Gastric_Disinfectant__The_Complex.13.aspx

Murray LJ, Lane AJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Inverse relationship between alcohol consumption and active Helicobacter pylori infection: The Bristol Helicobacter Project. Am J Gastroenterol. 2002; 97:2750-2755. https://insights.ovid.com/pubmed?pmid=12425543

Marimon JM, Bujanda L, Gutierrez-Stampa MA, Cosme A, Arenas JI. In vitro bactericidal effect of wine against Helicobacter pylori. Am J Gastroenterol. 1998; 93:1392. https://insights.ovid.com/pubmed?pmid=9707086

Glupczynski Y. Culture of Helicobacter pylori from biopsies and antimicrobial susceptibility testing. In: Megraud F, Lee A, eds. Helicobacter pylori: Techniques for Clinical Diagnosis and Basic Research, Oxford: WB Saunders Company, p. 17-32. 1996.

Megraud F, Lee A. Helicobacter pylori: Techniques for Clinical Diagnostics and Basic Research. Oxford: WB Saunders Company; 1996.

CLSI/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Approved Standard M100-S19. Wayne: CLSI; 2009.

National Committee for Clinical Laboratory Standards (NCCLS). Development of in vitro Susceptibility Testing Criteria and Quality Control Parameters, 5th Ed. Philadelphia: American Society for Testing of Materials; 2018.

Oleastro M, Gerhard M, Lopes AI, Ramalho P, Cabral J, Guerreiro AS, et al. Helicobacter pylori virulence genotypes in Portuguese children and adults with gastroduodenal pathology. Eur J Clin Microbiol Infect Dis. 2003; 22:85-91. https://link.springer.com/article/10.1007/s10096-002-0865-3

Tummuru MKR, Cover TL, Blaser MJ. Cloning and expression of a high-molecular- mass major antigen of Helicobacter pylori: Evidence of linkage to cytotoxin production. Infect Immun. 1993; 61:1799-1809. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280768/

Atherton JC, Cao P, Peek RM. Mosaicism in the vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995; 270:17771-17779. https://www.sciencedirect.com/science/article/pii/S0021925817480100?via%3Dihub

Roggero JP, Coen S, Archier P, Rocheville-Divorne C. Etude par C.L.H.P. de la reaction glucoside de malvidine-acetaldehyde-compose phenolique. Conn Vigne Vin. 1987; 21:163-168. https://oeno-one.eu/article/view/1283

Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007; 20:280-322. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865594/

Ecclissato C, Marchioretto MAM, Mendonça S, Godoy APO, Guersoni RA, Deguer M, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter. 2002; 7:53-59. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1523-5378.2002.00056.x?sid=nlm%3Apubmed

Lee SY, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis. 2008; 9:129-139. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1751-2980.2008.00334.x

Daroch F, Hoeneisen M, Gonzalez CL, Kawaguchi F, Salgado F, Solar H, et al. In vitro antibacterial activity of Chilean red wines against Helicobacter pylori. Microbios. 2001; 104:79-85. https://pubmed.ncbi.nlm.nih.gov/11297014/

Just JR, Daeschel MA. Antimicrobial effects of wine on Escherichia coli O157:H7 and Salmonella typhimurium in a model stomach system. J Food Sci. 2003; 68:285- 290. https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2621.2003.tb14154.x

Møretrø T, Daeschel MA. Wine is bactericidal to foodborne pathogens. J Food Sci. 2004; 69:M251-257. https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2621.2004.tb09938.x

Friedman M. Antibacterial, antiviral, and antifungal properties of wines and winery byproducts in relation to their flavonoid content. J Agric Food Chem. 2014; 62:6025- 6042. https://pubs.acs.org/doi/10.1021/jf501266s

Kamei H, Hashimoto Y, Koide T, Kojima T, Hasegawa S. Anti-tumor of methanol extracts from red and white wines. Cancer Biother Radiopharm. 1998; 13:447-452. https://www.liebertpub.com/doi/10.1089/cbr.1998.13.447?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&

Belleville J. The French paradox: possible involvement of ethanol in the protective effect against cardiovascular diseases. Nutrition. 2002; 18:173-177.

Daglia, M. Polyphenols as antimicrobial agents. Curr Opin Biotechnol. 2012; 23:174- 181. https://www.sciencedirect.com/science/article/pii/S0899900701007213?via%3Dihub

Mahady GB, Pendland SL. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol. 2000; 95:1849. https://insights.ovid.com/pubmed?pmid=10926010

Wang D, Xu Y, Liu W. Tissue distribution and excretion of resveratrol in rat alter oral administration of Polygonum cuspidatum extract (PCE). Phytomedicine. 2008; 15:859-866. https://www.sciencedirect.com/science/article/pii/S0944711308000287?via%3Dihub

Orallo F. Trans-resveratrol: a magical elixir of eternal youth?. Curr Med Chem. 2008; 15:1887-1898. https://pubmed.ncbi.nlm.nih.gov/18691046/

Mahady GB, Pendland SL, Chadwick LR. Resveratrol and red wine extracts inhibit the growth of CagA + strains of Helicobacter pylori in vitro. Am J Gastroenterol. 2003; 98:1440-1441. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860858/

Dong W, Zhon Y, Yang Z. Research progress of mechanism of action of resveratrol. Pharmacol Pharm. 2016; 7:170-175. DOI: 10.4236/pp.2016.74022

Ghiara P, Marchetti M, Blaser MJ, Tummuru MK, Cover TL, Segal ED, et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun. 1995; 63:4154-4160. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC173584/

Salama NR, Otto G, Tompkins L, Falkow S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun. 2001; 69:730-736. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC97945/

Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious disease. Phytomedicine. 2008; 15:639-652. https://www.sciencedirect.com/science/article/pii/S0944711308001104?via%3Dihub

Sung WG, Lee DG. Mechanism of decreased susceptibility for Gram-negative bacteria and synergistic effect with ampicillin of indole-3-carbinol. Biol Pharm Bull. 2008; 31:1798-1801. https://pubmed.ncbi.nlm.nih.gov/18758080/

Descargas

Publicado

2021-12-23

Cómo citar

Catalao Dionisio , L. P., Labella , A. M., Palma , M. ., & Borrego , J. J. . (2021). Actividad antimicrobiana in vitro de los vinos del Duero sobre cepas clínicas de Helicobacter Pylori . Nova, 19(37), 121–134. https://doi.org/10.22490/24629448.5499

Número

Sección

Investigación original